Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...

The number of women dying during or soon after pregnancy in the UK is higher today than 10 years ago,1 with shocking reports of avoidable deaths, as articulated by The Lancet.2 ...

At least twice as many patients on the approved spesolimab dose maintain improvement in skin symptoms and quality of life ...

"We're thrilled to welcome Gagandeep Singh Bedi, his rare combination of corporate leadership and deep engagement with the ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

But for Ozzie and his wife Andreia, it’s about more than puppy paparazzi. “It’s special because I always grew up having dogs, ...

The BioMed X Institute has launched a new global call for research proposals in collaboration with Boehringer Ingelheim.

A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical ...

Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, lowered FVC decline vs. placebo in patients with ...

Germany’s Boehringer Ingelheim GmbH filed with regulators in the US, China and Europe to sell a new treatment for lung ...